Sun Pharmaceutical has launched a medication to treat Erosive Esophagitis

Sun Pharmaceutical Industries has introduced Fexuclue in India, which comprises Fexuprazan tablets (40mg) to treat Erosive Esophagitis of all grades.

This potassium-competitive acid blocker (PCAB) is a novel treatment of adults and licensed from Daewoong Pharmaceuticals of South Korea. Daewoong will be receiving upfront and milestone payments along with royalties.

Fexuprazan has been proved efficacious in a Phase 3 study in Indian adults. Among the patients in the study population, the endpoint for endoscopic healing from Erosive Esophagitis was achieved in more than 95% within eight weeks. This study was a double blind, double dummy comparative study.

The launch marks the expansion of Sun Pharma's gastrointestinal portfolio, bringing in a new treatment. There was a 2.97% crash in the shares of Sun Pharma, which traded at Rs 1,658.60 on the BSE.

Kirti Ganorkar, Sun Pharma CEO India Business said, "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. Fexuclue is a best-in-class treatment option with the potential to bridge this gap."

Sun Pharma, the largest pharmaceutical company in India, develops and markets a repo of drugs across the globe, known for generics and specialty medication and has a considerable international presence and history of acquiring other companies for growth.